GREENVILLE, S.C., Jan. 8 /PRNewswire-FirstCall/ -- Signalife, Inc.
(Amex: SGN), the revolutionary heart monitoring company, announced today
that it has completed -- for fabrication and ultimate distribution -- its
one-of-a-kind cardiac vest that utilizes Signalife's patented signal
amplification technology to allow for precise ECG monitoring of athletes
and patients in harsh ambulatory environments.
The cardiac vest, featured on November 30, 2006 in an NBC Today Show's
segment ("Modern Medical Miracles"), has been extensively utilized in
testing in the Champ Car World Series open cockpit racing. During these
tests, the ECG signals have allowed physicians to evaluate data previously
unavailable when captured in the very harsh environment of a race car.
In present cardiac devices, noise and artifact distort ECG recordings
in an ambulatory setting. In addition, uncomfortable sticky electrodes are
placed on the patient's torso prior to testing. Skin preparation, which may
include shaving hair or skin abrading, is often necessary without the
Signalife vest. The Signalife proprietary vest features dry (e.g.,
quarter-size, metal) electrodes embedded in a cloth fabric which provide
better comfort and reduced skin irritation for a large percentage of the
clients or patients.
Signalife is aware of no other system that can acquire a similar ECG
signal in any ambulatory environment with the use the metal electrodes
compatible with Signalife's cardiac vest.
With these approvals, Signalife will now proceed to submit the vest for
accelerated FDA clearance and rapid movement into the marketplace. The
completion of the cardiac vest coincides with Signalife's business plans to
"time" its Gold's Gym initiative with the Company's other exercise
programs. The first Gold's Gym facility is fully built out, complete with
-- among other things -- the cardiac center and other tools to assist the
clientele and physicians in screening related to inherent cardiovascular
Budimir Drakulic, the Company's Chief Technology Officer, indicated
that he was "very satisfied with the development of the vest and its
performance during the Champ Car testing." Dr. Drakulic said: "Given the
difficulty surrounding the recording of electrocardiographic data during
car races, Signalife's R&D team -- and particularly Marko Kostic, the
Company's Champ Car project leader -- deserves praise for the successful
development of the cardiac vest and accompanying systems.
The performance of the vest can be witnessed on video within
Signalife's website, www.signalife.com, or by clicking on
Signalife, Inc. is a medical device company focused on the detection of
cardiovascular disease through continuous ECG signal monitoring. The
company's goal is to become the premier provider of cardiovascular disease
monitoring products. Signalife uses its patented signal technology to
design and develop medical devices that simplify and reduce the costs of
diagnostic testing and patient monitoring in an ambulatory environment.
Signalife's revolutionary FDA-approved electrocardiograph (ECG) monitoring
system called Fidelity 100 allows for the recording of a quality ECG signal
from ambulatory cardiac patients. The Fidelity 100 will address a portion
of the $400 billion cardiac disease market. Signalife, Inc. is traded on
the American Stock Exchange under the symbol SGN. The company's website is
available at: http://www.signalife.com
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are
"forward- looking" statements. Forward-looking statements involve known and
unknown risks, which may cause Signalife, Inc. results in the future to
differ materially from expected results. Factors which could cause or
contribute to such differences include, but are not limited to, failure to
complete the development and introduction of new products or services,
failure to obtain federal or state regulatory approval governing medical
devices, monitoring and other related services or products, inability to
obtain physician, patient or insurance acceptance of Signalife's products
or services, adverse equity market conditions and declines in the value of
Signalife's common stock, and the unavailability of financing to complete
management's plans and objectives. These risks are qualified by cautionary
language and risk factors set forth and to be further described in
Signalife's filings with the Securities and Exchange Commission.
SOURCE Signalife, Inc.